No Data
No Data
Last week's topic report: Stocks with significant revisions from financial estimates made by analysts.
As the Nikkei average continues to linger around ¥39,000 and analysts show a bullish outlook, attention is focused on the stocks that are expected to result in upward revisions to company plans. While it is anticipated that the difficult material situation will result in a development that is difficult to determine, East Tokyo Intelligence Lab is focusing on stock selection focusing on corporate performance. While the company plan for the March 2025 period predicts a decline in current profits compared to the previous year (for TOPIX1000), it is lackluster, and the company is seeking to refocus on stock selection focusing on corporate performance.
Kissei Pharmaceutical: Extraordinary Report
List of Conversion Stocks (Part 1) [List of Parabolic Signal Conversion Stocks]
List of stocks for buying and converting: Market Code Name Ending Price SAR Tokyo Stock Exchange 1332 Nissui 867 833 1333 Maruha Nichiro 3228 3067 1605 INPEX 2388 2264 1720 Tokyu Construction 764 746 1808 Haseko
Kissei Pharmaceutical: Securities Report - 79th Fiscal Year (April 1, 2023 - March 31, 2024)
Kissei Pharmaceutical: Confirmation letter
Check disclosure information for "Tomorrow's Good and Bad Materials"! (Announcement on June 10th).
【Good Materials】- - - - - - - - - - - - ■Trial Holdings [TSE G] Same-store sales in May increased by 5.2% compared to the same month last year, continuing the trend of revenue growth. ■Tamahome [TSE P] May order intake exceeded the previous year's performance for the first time in 5 months, increasing by 13% compared to the same month last year. ■Green Energy & Company [TSE G] This year's ordinary profit is expected to increase by 12%, and dividends are expected to increase by 1 yen. ■Morozoff [TSE P] 2-
No Data